Epidemiological studies of cholesterol management by statin treatment in 2012 edition of atherosclerotic cardiovascular disease prevention guidelines - A study of the Japan lipid management view (J-LiView)

Japanese Pharmacology and Therapeutics

Volumn 41, Issue 5, 2013, Pages 415-424

  Teramoto, Tamio ^a   Kokubo, Kinya ^b   Mototani, Takahiro ^b   Yatsunami, Satoru ^b  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Nomura Research Institute Consumer Goods   (Japan)

Author keywords

Chronic kidney disease (CKD); Epidemiological studies; Revised clinical practice guidelines; Statin monotherapy

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PITAVASTATIN; ROSUVASTATIN;

ARTICLE; CORONARY ARTERY DISEASE; DATA BASE; HIGH RISK BEHAVIOR; HUMAN; HYPERCHOLESTEROLEMIA; MEDICAL RECORD REVIEW; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 84879164558     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Teramoto T, Kashiwagi A, Mabuchi H, Aso M. : for the J-LAP Investigators. Status of lipid lowering therapy prescribed based on recommendations in the 2002 report of the Japan artherosclerosis society guideline for daiagnosis and treatment of hyperlipidemia in Japanese adults : a study of the Japan Lipid Assessment Program (J-LAP). Curr Ther Res Clin Exp 2005; 66 : 80-90. (Pubitemid 40798034)
2. Tada N, Yoshida H, Teramoto T, Oikawa S, Saito Y, Yamada N, et al. A survey to evaluate the status of lipid-lowering therapy and risk factors in patients with high low-density lipoproterol level or low high density lipoproterol level in Japan : lipid management program in Japan. Seijinbyo to Seikaatsyukanbyo 2005; 35 : 1187-97.
3. Teramoto T, Kashiwagi A, Ishibashi S, Daida H. Cross-sectional survey to assess the status of lipid management in high-risk patients with dyslipidemia : clinical impact of combination therapy with Ezetimibe. Curr Ther Res 2012; 73 : 1-15.
4. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Diabetes and cardiovascular disease in a prospective population survey in Japan : the Hisayama study. Diabetes 1996; 45 : 14-6.
5. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication : a risk profile from the Framingham heart study. Circulation 1997; 96 : 44-9. (Pubitemid 27298402)
6. Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M, et al. LDL cholesterol and the Development of Stroke Subtypes and Coronary Heart Disease in a General Japanese Population : The Hisayama study. Stroke 2009; 40 : 382-8.
7. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. : SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebo controlled trial. Lancet 2011; 377 : 2181-92.
8. Uchiyama S, Goto S, Matsumoto M, Nagai R, Origasa H, Yamazaki T, et al. : REduction of Atherothrombosis for Cotinued Health Registry Investigators. Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular location : Results from 1-year outcome in the Japan REACH Registry. J Neurol Sci 2008; 287 : 45-51.
9. Shigematsu H, Nishibe T, Obitsu Y, Matsuzaki K, Ishida A, Miyata T, et al. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease : results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD). Int Angiol 2010; 29 : 2-13.
10. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk : consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. JACC 2008; 51 : 1512-24. (Pubitemid 351470037)
11. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults : executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285 : 2486-97.